NCT03095456 - Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

November 25, 2017

Study Completion Date

November 25, 2017

Conditions

Chronic Obstructive Pulmonary Disease, COPDLow Peak Inspiratory Flow Rate (PIFR)

Interventions

DRUG

Revefenacin

Revefenacin administered via nebulization.

COMBINATION_PRODUCT

Spiriva Handihaler®

Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.

DRUG

Placebo for Revefenacin

Placebo administered as double blind, double dummy via nebulization.

DRUG

Placebo for Spiriva Handihaler®

Placebo administered as double blind, double dummy via Spiriva HandiHaler®.

Trial Locations (1)

Clinical Research of Rock Hill, Rock Hill